Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Feb 11, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	5,720	$314.31	1,252,086
Feb 11, 2014	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	94,756	$314.31	1,157,330
Dec 12, 2013	YANCOPOULOS GEORGE Director, Pres Regeneron Labs	Director, Pres Regeneron Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	9,154	$273.06	1,106,840
Dec 12, 2013	YANCOPOULOS GEORGE Director, Pres Regeneron Labs	Director, Pres Regeneron Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	228	$273.06	1,106,612
Dec 16, 2013	YANCOPOULOS GEORGE Director, Pres Regeneron Labs	Director, Pres Regeneron Labs	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	42,974	$272.73	1,063,638
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	400	$264.21	1,106,395
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	38,267	$263.22	1,106,795
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	47,876	$262.43	1,145,062
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	13,457	$261.66	1,192,938
Dec 12, 2013	YANCOPOULOS GEORGE Director, Pres Regeneron Labs	Director, Pres Regeneron Labs	Form 4	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	9,599	$260.44	1,115,994

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media